ClinicalTrials.gg
CompletedNCT04100473T2DMUpdated Sep 24, 2019

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Inhaled Human Insulin and Insulin Lispro (Humalog U-100) in Type 2 Diabetes Mellitus, sponsored by Dance Biopharm Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Dance Biopharm Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Apr 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
37th of 49
24 · median 129
Started
2018
the only one that year
Phase 2
8 of 49
none open now
Registered
46th of 49
by date
Lead sponsor
1 of 49
Dance Biopharm Inc.

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 46th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)

Read the detailed description

To assess the dose-response and dose-exposure of Dance 501 (Human Insulin Inhalation Solution) administered with the Dance 501 Inhaler.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Inhaled Insulin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with T2DM.
  • between 25.0 and 40.0 kg/m2.
  • Treated with metformin and/or at least 1 daily injection of insulin for at least 6 months.
  • Non-smoker for at least 5 years.
  • Forced vital capacity and is at least 75% normal.

Exclusion criteria

Exclusion Criteria:

  • Any condition affecting pulmonary drug absorption.
  • History or presence of cancer except basal cell skin cancer or squamous cell skin cancer.
  • Serious systemic infectious disease during four weeks prior to dosing.
  • abnormal lab values.
  • Proliferative retinopathy and/or severe neuropathy.
  • Recurrent severe hypoglycemia.
  • Current treatment with oral anti-diabetic drugs except metformin, glucagon-like peptide receptor agonists.
  • Current treatment with MAO inhibitors.
  • Unstable Thyroid hormones for at least 3 months.
  • Insufficient glycemic control with significant fluctuations of blood glucose.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dance 501

    Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.

    Drug: Inhaled Human Insulin

  • Active comparator
    Insulin Lispro

    Insulin Lispro (Humalog®) will be administered by subcutaneous injection.

    Drug: Insulin Lispro (Humalog U-100)

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Pharmacokinetic Endpoint - PK 1

    Area under the human insulin and insulin lispro concentrations time curves

    Time frame: 0 - 10 hours

  2. Primary Pharmacokinetic Endpoint - PK 2

    Maximum observed concentration of human insulin and insulin lispro

    Time frame: 0 - 10 hours

  3. Primary Pharmacodynamic Endpoint - PD 1

    Area under the glucose infusion rate time curve

    Time frame: 0 - 10 hours

  4. Primary Pharmacodynamic Endpoint - PD 2

    Maximum observed glucose infusion rate

    Time frame: 0 - 10 hours

Secondary outcomes

  1. Secondary Pharmacokinetic Endpoint - PK 1

    Area under the insulin time curves at different intervals

    Time frame: 0 - 1 hour, 0 - 2 hours, 0 - 8 hours

  2. Secondary Pharmacokinetic Endpoint - PK 2

    Time to maximum insulin concentrations

    Time frame: 0 - 10 hours

  3. Secondary Pharmacokinetic Endpoint - PK 3

    Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro

    Time frame: 0 - 10 hours

  4. Secondary Pharmacokinetic Endpoint - PK 4

    Onset of appearance (time from trial product administration until the serum insulin concentrations are \> LLOQ.

    Time frame: 0 - 10 hours

  5. Secondary Pharmacokinetic Endpoint - PK 5

    Mean residence time of insulin

    Time frame: 0 - 10 hours

  6. Secondary Pharmacodynamic Endpoint - PD 1

    AUC for GIR at different time intervals

    Time frame: 0 - 1 hour, 0 - 2 hours, 0 - 8 hours

  7. Secondary Pharmacodynamic Endpoint - PD2

    Time to maximum glucose infusion rate

    Time frame: 0 - 10 hours

  8. Secondary Pharmacodynamic Endpoint - PD3

    Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro

    Time frame: 0 - 10 hours

07

Study locations

1 site
  • Profil Mainz
    Mainz, Malakoff-Passage, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2018, 3 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2019
First posted
Sep 24, 2019
StartActual
Apr 23, 2018
Primary completionActual
Aug 11, 2018
CompletionActual
Aug 1, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04100473
Lead sponsor
Dance Biopharm Inc.
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
Apr 23, 2018
Primary completion
Aug 11, 2018
Completion
Aug 1, 2019
Last update
Sep 24, 2019

Study contacts

Oliver Klein
principal investigator · Profil Institut fur Stoffwechselforschung GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion